After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of BridgeBio Pharma Inc is $9.89B. A total of 2.99 million shares were traded on the day, compared to an average of 2.89M shares.
In the most recent transaction, Trimarchi Thomas sold 42,237 shares of BBIO for 49.48 per share on Aug 21 ’25. After the transaction, the President and CFO now owns 421,081 company shares. In a previous transaction on Aug 20 ’25, Kumar Neil sold 26,156 shares at 48.82 per share. BBIO shares that Chief Executive Officer owns now total 223,090.
Among the insiders who bought shares, THOMAS TRIMARCHI acquired of 42,237 shares on Aug 21 ’25 at a per-share price of $49.48. In another insider transaction, NEIL KUMAR bought 26,156 shares at $48.91 per share on Aug 20 ’25.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, BBIO has a high of $52.60 and a low of $21.72.
As of this writing, BBIO has an earnings estimate of -$0.7 per share for the current quarter. EPS was calculated based on a consensus of 5.0 estimates, with a high estimate of -$0.45 per share and a lower estimate of -$1.01. The company reported an EPS of -$1.08 in the last quarter
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. BBIO’s latest balance sheet shows that the firm has $836.66M in Cash & Short Term Investments as of fiscal 2021. There were $1.73B in debt and $135.07M in liabilities at the time. Its Book Value Per Share was -$9.35, while its Total Shareholder’s Equity was -$865.58M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BBIO is Buy with a score of 4.77.
